2005
DOI: 10.1038/sj.bjc.6602671
|View full text |Cite
|
Sign up to set email alerts
|

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours

Abstract: The goal of this phase I study was to develop a novel schedule using oral etoposide and infusional topotecan as a continually alternating schedule with potentially optimal reciprocal induction of the nontarget topoisomerase. The initial etoposide dose was 15 mg m À2 b.i.d. days (D)1 -5 weeks 1,3,5,7,9 and 11, escalated 5 mg per dose per dose level (DL). Topotecan in weeks 2,4,6,8,10 and 12 was administered by 96 h infusion at an initial dose of 0.2 mg m À2 day À1 with a dose escalation of 0.1, then at 0.05 mg … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2011
2011
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
references
References 25 publications
0
0
0
Order By: Relevance